Effect of the Number of Core Biopsies of the Prostate on Predicting Gleason Score of Prostate Cancer

Predictive accuracy of transrectal ultrasound-guided prostate biopsy: correlations to matched prostatectomy specimens

OBJECTIVES

To characterize observed differences in Gleason score between prostate biopsy and corresponding radical retropubic prostatectomy (RRP) specimens.

METHODS

One hundred consecutive clinically localized prostate cancers diagnosed by transrectal ultrasound-guided biopsy (TRUS-Bx) and treated with RRP were reviewed. All specimens were evaluated in blinded review by a single expert uropathologist and contrasted with the initial histologic analysis, performed by multiple pathologists.

RESULTS

Mean Gleason score of TRUS-Bx specimens for blinded review and at initial evaluation were 6.6 +/- 0.1 and 6.0 +/- 0.1 (P < 0.001). Corresponding RRP values were 6.8 +/- 0.1 and 6.5 +/- 0.1 (P < 0.03). Differences in Gleason score between TRUS-Bx and RRP at initial evaluation were significant (P < 0.02), but not in blinded review (P = NS). In blinded review, TRUS-Bx correctly predicted RRP histology for 88% of men with lesions scored as Gleason 5 to 7 and 41% of men with well-(Gleason score of 2 to 4) or poorly differentiated (Gleason score of 8 to 10) lesions (P < 0.01).

CONCLUSIONS

TRUS-Bx does not accurately reflect RRP histology when predicting well- or poorly differentiated lesions. Prostate cancer treatment algorithms should not be predicated upon biopsy histology alone. Histologic interpretation is more accurate and precise when performed by a single experienced uropathologist.

p53 protein expression as prognostic factor in patients undergoing radical prostatectomy for prostatic cancer

The authors give preliminary data on the evaluation of the p53 protein expression as prognostic factor in patients subjected to radical prostatectomy for prostatic cancer. p53 protein immunohistochemical nuclear staining was carried out on neoplastic tissue obtained from systematic sextant prostatic biopsies at the time of diagnosis. Out of 46 Patients 15 (32%) were p53 positive (p53+). No statistical correlation was observed between P53 staining, preoperative PSA and pathological Gleason Score, while the rate of patients with nodal involvement (pN+) was higher in the p53+ group than the P53- group with low statistical significance (p<0.03). The authors cannot yet evaluate Progression time and survival because the mean follow-up of the patients is still too short (30 months). The study is still in progress.